- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01499758
A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.
July 8, 2012 updated by: Ranbaxy Laboratories Limited
This study assessed the relative bioavailability of 80 mg Atorvastatin Calcium Tablets (containing atorvastatin calcium equivalent to 80 mg atorvastatin) manufactured by OHM Laboratories, Inc., USA (A subsidiary of Ranbaxy Pharmaceuticals., USA) compared to that of 80 mg LIPITOR® Tablets (containing atorvastatin calcium equivalent to 80 mg atorvastatin) distributed by Parke Davis, Division of Pfizer Inc., USA following a single oral dose (1 x 80 mg tablet) in healthy adult subjects when administered under fasting conditions.
Study Overview
Detailed Description
This was an open-label, balanced, randomized, two-period, two-treatment, two-sequence, single-dose crossover bioequivalence study under fasting conditions.
The total duration of the study, screening through study exit, was approximately 8 weeks with at least a 14-day washout period between doses.
At study check-in, the subjects reported to the clinical site at least 36 hours prior to Day 1 dosing and were required to stay for 24 hours after Day 1 dosing.
Blood sample collections were obtained within 90 minutes prior to dosing (0 hour) and after dose administration at 0.167, 0.25, 0.333, 0.417, 0.5, 0.583, 0.667, 0.833, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 36, 48, 60, 72, and 96 hours.
A total of 30 blood samples were collected per study period for a total of 60 samples or 180 mL total volume.
Study Type
Interventional
Enrollment (Actual)
80
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Dakota
-
Fargo, North Dakota, United States, 58104
- Cetero Research 4801 Amber Valley Parkway
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed of the nature of the study, had agreed to, and was able to read, review, and sign the informed consent document prior to Period I dosing. The informed consent document was written in English, therefore the volunteer must have had the ability to read and communicate in English.
- Completed the screening process within 4 weeks prior to Period I dosing.
- Healthy male or female, 18 years of age or older at the time of dosing.
- Body mass index (BMI) between 18 - 32 kg/m2, inclusive, and weighed at least 110 lbs.
- Generally healthy as documented by medical history, physical examination (including but not limited to an evaluation of the cardiovascular, gastrointestinal, respiratory, and central nervous systems), vital sign assessments, 12-lead ECG, clinical laboratory assessments, and by general observations. Any abnormalities/deviations from the acceptable range that might have been considered clinically relevant by the study physician or investigator were evaluated as individual cases, documented in study files, and agreed upon by the principal investigator (or sub-investigator) prior to enrolling the subject in this study.
Female subjects were:
- of postmenopausal status (no menses) for at least one year and if < 55 years of age had documented FSH level ≥ 40 mIU/mL; or,
- sterile [surgically (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) or the Essure® Procedure].
Female subjects that were surgically sterile were to provide documentation of the bilateral tubal ligation, bilateral oophorectomy, or hysterectomy prior to Period I dosing. The Essure® Procedure must have been inserted at least 3 months prior with documentation of the Essure® confirmation test prior to Period I dosing.
Exclusion Criteria:
- Reported receiving any investigational drug within 28 days prior to Period I dosing.
- Reported any presence or history of a clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease as determined by the clinical investigator(s).
- Clinical laboratory test values outside the accepted range and when confirmed on re-examination was deemed to be clinically significant.
- When confirmed upon additional testing, demonstrates a reactive screen for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody.
- Reported a clinically significant illness during the 28 days prior to Period I dosing (as determined by the clinical investigators).
- Demonstrated a positive drug screen or alcohol breath test.
- Reported a history of allergic response(s) to atorvastatin or related drugs.
- Reported a history of clinically significant allergies including food or drug allergies.
- Reported a history of drug or alcohol addiction or abuse within the past year.
- Reported donating blood within 28 days prior to Period I dosing. All subjects were to be advised not to donate blood for four weeks after completing the study.
- Reported donating plasma (e.g. plasmapheresis) within 14 days prior to Period I dosing. All subjects were to be advised not to donate plasma for four weeks after completing the study.
- Reported an intolerance of direct venipuncture.
- Reported difficulty fasting or consuming standardized meals.
- Reported difficulty swallowing tables or capsules whole.
- Pregnant, lactating, breastfeeding, or intended to become pregnant over the course of the study (females only).
- Demonstrates a positive pregnancy screen (female only).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Atorvastatin Calcium Tablets of OHM Laboratories Inc.
|
80 Mg tablets
|
Active Comparator: 2
LIPITOR® Tablets 80mg of Pfizer Ireland Pharmaceuticals
|
80 Mg tablets
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area under the plasma concentration versus time curve (AUC) and Peak Plasma Concentration (Cmax) of Atorvastatin.
Time Frame: 0, 0.167, 0.25, 0.333, 0.417, 0.5, 0.583, 0.667, 0.833, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 36, 48, 60, 72, and 96 hours.
|
0, 0.167, 0.25, 0.333, 0.417, 0.5, 0.583, 0.667, 0.833, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16, 20, 24, 36, 48, 60, 72, and 96 hours.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
October 1, 2009
Study Completion (Actual)
December 1, 2009
Study Registration Dates
First Submitted
December 20, 2011
First Submitted That Met QC Criteria
December 22, 2011
First Posted (Estimate)
December 26, 2011
Study Record Updates
Last Update Posted (Estimate)
July 10, 2012
Last Update Submitted That Met QC Criteria
July 8, 2012
Last Verified
June 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R09-1032
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Atorvastatin
-
GlaxoSmithKlineCompletedDiabetes Mellitus, Type 2Korea, Republic of, Malaysia, Philippines, Thailand, Russian Federation, Mexico
-
Organon and CoCompleted
-
Obafemi Awolowo University Teaching HospitalOpen PhilanthropyRecruitingTuberculosis | Pulmonary Tuberculosis | Koch's DiseaseNigeria
-
PfizerCompletedHypertriglyceridemia | Hyperlipoproteinemia Type IVUnited States, Canada
-
Hippocration General HospitalCompletedCoronary Artery Disease | Atherosclerosis | Endothelial Dysfunction | Oxidative Stress | HMG-CoA Reductase Inhibitor ToxicityGreece
-
St. Olavs HospitalUllevaal University Hospital; Oslo University Hospital; University Hospital of... and other collaboratorsNot yet recruiting
-
Organon and CoCompleted
-
Zhejiang Hisun Pharmaceutical Co. Ltd.Unknown
-
Zhongda HospitalNot yet recruitingAcute Ischemic Stroke | Mechanical ThrombectomyChina